Natco Pharma concludes USFDA inspection of its API unit in Chennai
With seven observation under Form 483
Natco Pharma today announced conclusion of US FDA Inspection at its Manali, Chennai, Active Pharmaceutical Ingredients (API) Unit. The inspection was conducted from 17 - 21 November 2025.
On conclusion of the inspection, the Company received seven observations in the Form-483. The Company believes that the observations are procedural in nature. The Company is confident to address these observations comprehensively.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content